menu
    • menu
    [{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc Macroaggregated Albumin","moa":"Albumin","graph1":"Oncology","graph2":"Phase I","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"6","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"BTG INTERNATIONAL INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Foam","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Foam","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"BTG INTERNATIONAL INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Oncology","graph2":"Phase I","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"6","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"8","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Hematology","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ BTG International Inc","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ BTG International Inc"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Crotalidae Immune Fab","moa":"Venom toxin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by BTG INTERNATIONAL INC

    Menu

    BTG INTERNATIONAL INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous Syste...

                            Details : Glucarpidase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            November 26, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Macroaggregated Albumin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for D...

                            Details : 99m-Tc Macroaggregated Albumin is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 26, 2019

                            Lead Product(s) : 99m-Tc Macroaggregated Albumin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polidocanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : OhioHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs

                            Details : Polidocanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2016

                            Lead Product(s) : Polidocanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : OhioHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

                            Details : Alteplase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Embolism.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 24, 2015

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endov...

                            Details : Alteplase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            June 10, 2014

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crotalidae Immune Fab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation

                            Details : Crotalidae Immune Fab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Snake Bites.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 29, 2013

                            Lead Product(s) : Crotalidae Immune Fab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

                            Details : Folinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

                            Details : Alteplase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Embolism.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 20, 2012

                            Lead Product(s) : Alteplase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BTG INTERNATIONAL INC

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polidocanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

                            Details : Polidocanol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Varicose Veins.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 02, 2011

                            Lead Product(s) : Polidocanol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Boston Scientific

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth